Extraction And Biological Evaluation Of A Plant From Papaveraceae Family Argemone Mexicana

Abstract

After stroke and Alzheimer s disease, epilepsy is the third most common neurological disorder. newlineMedicinal plants possess enormous importance for the management of various diseases, newlinetraditionally. Besides, quality-based assessment of herbal drugs or products is being more newlineconcerning for their quality, safety and regulatory purpose. A. mexicana is a traditional herbal newlinemedicine that has a long history in the treatment of arthritis, anti-fungal anti-cancer and brain disorders. Due to lack of scientific evidence based on phytopharmacology, the phytochemical and newlineanticonvulsant effect of the hydroalcoholic extract of Argemone mexicana (HAEAM) was newlinedetermined in maximal electroshock (MES) and pentylenetetrazole (PTZ) seizure tests. newlinePhytochemical identification was done using MS, FTIR and 1HNMR and quantitated using newlineHPTLC densitometric analysis. The HAEAM were orally administered and the occurrence of tonic newlineseizures induced by MES and clonic seizures induced by PTZ or were monitored. In addition, newlinebiochemical parameter such as antioxidant enzymes level were analyzed in the brain and also newlineevaluate the histological architecture of the hippocampus and cortex. Further, ADME and network newlinepharmacology studies were performed to evaluate the biological response of identified newlinemetabolites. The resulted outcomes of the spectral analysis suggest isolated compounds as ferulic newlineacid, caffeic acid, berberine and angoline. In HPTLC quantitative analysis, the content of ferulic newlineacid, caffeic acid, berberine and angoline was found as 3.475 ± 0.028, 1.036 ± 0.013, 0.714 ± 0.014 newlineand 0.738 ± 0.081 and#956;g/mg of A. mexicana extract. In the MES test, the HAEAM showed a newlinesignificant (p lt 0.05) anticonvulsant effect by decreasing the duration of hind limb extension newline(extensor phase), as compared to control. In the PTZ test, HAEAM showed a significant (p lt 0.05) newlineeffect as compared to control by delaying the onset of convulsions. The HAEAM treatment newlinesignificantly improved the enzymatic (CAT, SOD, and GSH) level in the brain.